Korean J Gastroenterol.  2021 May;77(5):241-247. 10.4166/kjg.2021.064.

How Should We Do Different Approach to Treat Inflammatory Bowel Disease by Gender Difference?

• Kim SE

• KMID: 2516041
• DOI: http://doi.org/10.4166/kjg.2021.064

Abstract

Although not as prominent, there are gender/sex differences in incidence/prevalence, clinical manifestation and disease course, comorbidities, therapeutic response, and patients coping strategy to the disease of inflammatory bowel disease (IBD). In this review, current knowledge about gender-specific differences in IBD would be provided and how to apply this in clinical practice be discussed.

Keyword

Inflammatory bowel diseases; Sex; Gender difference

Reference

1. Whitacre CC. 2001; Sex differences in autoimmune disease. Nat Immunol. 2:777–780. DOI: 10.1038/ni0901-777. PMID: 11526384.

2. Goodman WA, Erkkila IP, Pizarro TT. 2020; Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 17:740–754. DOI: 10.1038/s41575-020-0354-0. PMID: 32901108.

3. Shah SC, Khalili H, Chen CY, et al. 2019; Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region. Aliment Pharmacol Ther. 49:904–911. DOI: 10.1111/apt.15178. PMID: 30773656.

4. Moon JM, Kang EA, Han K, et al. 2020; Trends and risk factors of elderly-onset Crohn's disease: a nationwide cohort study. World J Gastroenterol. 26:404–415. DOI: 10.3748/wjg.v26.i4.404. PMID: 32063689. PMCID: PMC7002904.

5. Park SH, Kim YJ, Rhee KH, et al. 2019; A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis. 13:1410–1417. DOI: 10.1093/ecco-jcc/jjz081. PMID: 30989166.

6. Chan SSM. 2019; Editorial: differences in sex-based incidence of inflammatory bowel diseases between Asia-Pacific and Western countries - are these due to differences in environment, access to healthcare, or pathophysiology? Aliment Pharmacol Ther. 49:1098–1099. DOI: 10.1111/apt.15203. PMID: 30920050.

7. Shah SC, Khalili H, Gower-Rousseau C, et al. 2018; Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from western countries. Gastroenterology. 155:1079–1089. e3.

8. Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. 2008; The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 103:2394–2400. DOI: 10.1111/j.1572-0241.2008.02064.x. PMID: 18684177.

9. Ortizo R, Lee SY, Nguyen ET, Jamal MM, Bechtold MM, Nguyen DL. 2017; Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol. 29:1064–1070. DOI: 10.1097/MEG.0000000000000915. PMID: 28542115.

10. Khalili H, Higuchi LM, Ananthakrishnan AN, et al. 2013; Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 62:1153–1159. DOI: 10.1136/gutjnl-2012-302362. PMID: 22619368. PMCID: PMC3465475.

11. Severs M, Spekhorst LM, Mangen MJ, et al. 2018; Sex-related differences in patients with inflammatory bowel disease: results of 2 prospective cohort studies. Inflamm Bowel Dis. 24:1298–1306. DOI: 10.1093/ibd/izy004. PMID: 29688413.

12. Biedermann L, Fournier N, Misselwitz B, et al. 2015; High rates of smoking especially in female Crohn's disease patients and low use of supportive measures to achieve smoking cessation--data from the Swiss IBD cohort study. J Crohns Colitis. 9:819–829. DOI: 10.1093/ecco-jcc/jjv113. PMID: 26116554.

13. Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. 2004; Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol. 2:41–48. DOI: 10.1016/S1542-3565(03)00290-8.

14. Hwang SW, Seo H, Kim GU, et al. 2017; Underestimation of smoking rates in an east Asian population with Crohn's disease. Gut Liver. 11:73–78. DOI: 10.5009/gnl16194. PMID: 27728967. PMCID: PMC5221863.

15. Greuter T, Manser C, Pittet V, Vavricka SR, Biedermann L. on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. 2020; Gender differences in inflammatory bowel disease. Digestion. 101 Suppl 1:98–104. DOI: 10.1159/000504701. PMID: 31995797.

16. Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. 2009; Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 104:371–383. DOI: 10.1038/ajg.2008.38. PMID: 19174787.

17. Mazor Y, Maza I, Kaufman E, et al. 2011; Prediction of disease complication occurrence in Crohn's disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis. 5:592–597. DOI: 10.1016/j.crohns.2011.06.002. PMID: 22115380.

18. Blumenstein I, Herrmann E, Filmann N, et al. 2011; Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis. 5:203–210. DOI: 10.1016/j.crohns.2010.12.012. PMID: 21575882.

19. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. 2015; Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 21:1982–1992. DOI: 10.1097/MIB.0000000000000392. PMID: 26154136. PMCID: PMC4511685.

20. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. 2001; The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 96:1116–1122. DOI: 10.1111/j.1572-0241.2001.03756.x. PMID: 11316157.

21. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. 2012; Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 107:1693–1701. DOI: 10.1038/ajg.2012.298. PMID: 22945286. PMCID: PMC3572861.

22. Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. 2001; Gender-related differences in the clinical course of Crohn's disease. Am J Gastroenterol. 96:1541–1546. DOI: 10.1111/j.1572-0241.2001.03755.x. PMID: 11374696.

23. Song EM, Lee HS, Kim YJ, et al. 2020; Incidence and outcomes of perianal disease in an Asian population with Crohn's disease: a nationwide population-based study. Dig Dis Sci. 65:1189–1196. DOI: 10.1007/s10620-019-05819-9. PMID: 31485994.

24. Matos JF, Americo MF, Sinzato YK, et al. 2016; Role of sex hormones in gastrointestinal motility in pregnant and non-pregnant rats. World J Gastroenterol. 22:5761–5768. DOI: 10.3748/wjg.v22.i25.5761. PMID: 27433089. PMCID: PMC4932211.

25. Rolston VS, Boroujerdi L, Long MD, et al. 2018; The influence of hormonal fluctuation on inflammatory bowel disease symptom severity-a cross-sectional cohort study. Inflamm Bowel Dis. 24:387–393. DOI: 10.1093/ibd/izx004. PMID: 29361085. PMCID: PMC6196767.

26. Kane SV, Reddy D. 2008; Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 103:1193–1196. DOI: 10.1111/j.1572-0241.2007.01700.x. PMID: 18177456.

27. Gawron LM, Goldberger A, Gawron AJ, Hammond C, Keefer L. 2014; The impact of hormonal contraception on disease-related cyclical symptoms in women with inflammatory bowel diseases. Inflamm Bowel Dis. 20:1729–1733. DOI: 10.1097/MIB.0000000000000134. PMID: 25105949.

28. Beaugerie L, Itzkowitz SH. 2015; Cancers complicating inflammatory bowel disease. N Engl J Med. 373:195. DOI: 10.1056/NEJMra1403718.

29. Yoshino T, Nakase H, Takagi T, et al. 2016; Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study-CAPITAL (cohort and practice for IBD total management in Kyoto-Shiga Links) study I. BMJ Open Gastroenterol. 3:e000122. DOI: 10.1136/bmjgast-2016-000122. PMID: 27933204. PMCID: PMC5128829.

30. Söderlund S, Granath F, Broström O, et al. 2010; Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 138:1697–1703. DOI: 10.1053/j.gastro.2010.02.007. PMID: 20167217.

31. Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA. 2017; Corrigendum: malignancies in patients with inflammatory bowel disease (IBD): results from 20 years of follow-up in the IBSEN (inflammatory bowel south-eastern Norway) Study. J Crohns Colitis. 11:1511. DOI: 10.1093/ecco-jcc/jjw193. PMID: 28453756.

32. Caini S, Bagnoli S, Palli D, et al. 2016; Total and cancer mortality in a cohort of ulcerative colitis and Crohn's disease patients: the Florence inflammatory bowel disease study, 1978-2010. Dig Liver Dis. 48:1162–1167. DOI: 10.1016/j.dld.2016.07.008. PMID: 27481588.

33. Bourrier A, Carrat F, Colombel JF, et al. 2016; Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 43:252–261. DOI: 10.1111/apt.13466. PMID: 26549003.

34. Wu XR, Ashburn J, Remzi FH, Li Y, Fass H, Shen B. 2016; Male gender is associated with a high risk for chronic antibiotic-refractory pouchitis and ileal pouch anastomotic sinus. J Gastrointest Surg. 20:631–639. DOI: 10.1007/s11605-015-2976-z. PMID: 26446071.

35. Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. 2014; Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 8:469–479. DOI: 10.1016/j.crohns.2013.09.021. PMID: 24183231.

36. Cotton CC, Baird D, Sandler RS, Long MD. 2016; Hormonal contraception use is common among patients with inflammatory bowel diseases and an elevated risk of deep vein thrombosis. Inflamm Bowel Dis. 22:1631–1638. DOI: 10.1097/MIB.0000000000000800. PMID: 27306071. PMCID: PMC5064836.

37. Walldorf J, Krummenerl A, Engler K, et al. 2013; Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis. 7:901–907. DOI: 10.1016/j.crohns.2012.12.008. PMID: 23333038.

38. Han YM, Yoon H, Lim S, et al. 2017; Risk factors for vitamin D, zinc, and selenium deficiencies in Korean patients with inflammatory bowel disease. Gut Liver. 11:363–369. DOI: 10.5009/gnl16333. PMID: 28208007. PMCID: PMC5417778.

39. Häuser W, Janke KH, Klump B, Hinz A. 2011; Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis. 17:621–632. DOI: 10.1002/ibd.21346. PMID: 20848528.

40. van der Have M, van der Aalst KS, Kaptein AA, et al. 2014; Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis. 8:93–106. DOI: 10.1016/j.crohns.2013.04.007. PMID: 23746864.

41. Williet N, Sarter H, Gower-Rousseau C, et al. 2017; Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 11:165–174. DOI: 10.1093/ecco-jcc/jjw145. PMID: 27516406.

42. Jedel S, Hood MM, Keshavarzian A. 2015; Getting personal: a review of sexual functioning, body image, and their impact on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 21:923–938. DOI: 10.1097/MIB.0000000000000257. PMID: 25789923. PMCID: PMC4369789.

43. Sarid O, Slonim-Nevo V, Pereg A, et al. 2017; Coping strategies, satisfaction with life, and quality of life in Crohn's disease: a gender perspective using structural equation modeling analysis. PLoS One. 12:e0172779. DOI: 10.1371/journal.pone.0172779. PMID: 28245260. PMCID: PMC5330481.

44. Rubin DT, Feld LD, Goeppinger SR, et al. 2017; The Crohn's and colitis foundation of America survey of inflammatory bowel disease patient health care access. Inflamm Bowel Dis. 23:224–232. DOI: 10.1097/MIB.0000000000000994. PMID: 27997434.

45. Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. 2012; Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 6:143–153. DOI: 10.1016/j.crohns.2011.07.011. PMID: 22325168.

46. Campos S, Portela F, Sousa P, Sofia C. 2016; Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. Eur J Gastroenterol Hepatol. 28:1313–1319. DOI: 10.1097/MEG.0000000000000704. PMID: 27501126.

47. Billiet T, Dreesen E, Cleynen I, et al. 2016; A genetic variation in the neonatal fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease. Am J Gastroenterol. 111:1438–1445. DOI: 10.1038/ajg.2016.306. PMID: 27481307.

48. Billioud V, Sandborn WJ, Peyrin-Biroulet L. 2011; Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 106:674–684. DOI: 10.1038/ajg.2011.60. PMID: 21407178.

49. Eriksson C, Marsal J, Bergemalm D, et al. 2017; Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 52:722–729. DOI: 10.1080/00365521.2017.1304987. PMID: 28362144.

50. Lie MR, Kreijne JE, van der Woude CJ. 2017; Sex is associated with adalimumab side effects and drug survival in patients with Crohn's disease. Inflamm Bowel Dis. 23:75–81. DOI: 10.1097/MIB.0000000000000981. PMID: 28002127.

51. Lemaitre M, Kirchgesner J, Rudnichi A, et al. 2017; Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 318:1679–1686. DOI: 10.1001/jama.2017.16071. PMID: 29114832. PMCID: PMC5818785.